Karolinska Development’s portfolio company AnaCardio strengthens its organization to facilitate clinical trial of the drug candidate AC01 in heart failure
STOCKHOLM SWEDEN – October 25, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company AnaCardio has strengthened its organization in preparation for the initiation of a phase 1b/2a study of its drug candidate AC01 in patients with heart failure. The company's goal is to develop an orally available drug that, unlike current therapies, can affect the underlying cause of the disease. More than 100 million people suffer from heart failure, a potentially fatal condition with a one-year mortality rate of between 10 and 35 percent.
Anacardio has recently recruited Patrik Strömberg as its new CEO. He holds a PhD in biochemistry from Karolinska Institutet, an MBA from the Department of Business Administration at Stockholm University and has many years of experience in drug development and business development from leading positions within AstraZeneca and Sobi. Supported by a newly established management team that includes individuals with strong medical, regulatory and manufacturing expertise and extensive clinical trial experience, the company is now accelerating preparations for the planned start of a phase 1b/2a study evaluating the newly developed orally available drug candidate AC01 in patients with heart failure. The study is expected to be initiated in 2022.
“Karolinska Development's engagement in AnaCardio is an excellent example of how we can contribute to the creation of viable and commercially focused drug projects based on cutting-edge academic research. Since we became an owner in June this year, the company has secured all the necessary expertise to fast-track its unique drug candidate AC01 towards the first study in patients suffering from heart failure. We look forward to continuing to support the company in its efforts to develop a treatment that, unlike current drugs, can affect the underlying cause of the disease,” comments Karolinska Development's CEO Viktor Drvota.
The concept behind AC01 is based on studies showing that intravenous treatment with a specific peptide significantly improves heart function in patients with heart failure. In order to offer a more user-friendly treatment, AnaCardio has secured access to an orally available substance that is expected to provide the same benefits as this peptide, both in acute heart failure and in chronic treatment.
Karolinska Development holds 21% of the outstanding shares in AnaCardio.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: firstname.lastname@example.org
Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: email@example.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
JLT Mobile Computers acquires French sales partner ID Work8.12.2021 23:30:00 CET | Press release
With an own sales office JLT strengthens its local presence in the French market, which has grown to become one of the largest and most important regionsin Europe for JLT Växjö, Sweden, 8Dec2021 * * * JLT Mobile Computers, a leading supplier of reliable computers for demanding environments, today announced that they have signed the agreement to acquire of ID Work, their French sales partner with effect from January 2022. Since its start in 2013 ID Work has successfully been driving sales in France through a country-wide network consisting of system integrators and resellers. Since then, the French market has grown to become one of JLT’s largest and most important markets in Europe. JLT will be taking over the business and establish a local sales office with own personnel. Through the acquisition JLT will get closer to its customers and sales partners in France. The founder of ID Work, who is running the company today will have a continued involvement in JLT over the next couple of year
JLT Mobile Computers förvärvar sin franska säljpartner ID Work8.12.2021 23:30:00 CET | Pressemelding
Frankrike är ett av de största och viktigaste länderna i Europa för JLT ochsyftet med förvärvet är att etablera ett säljkontori egen regi för att stärkaden lokala närvaron Växjö, Sverige, 8:e december2021 * * * JLT Mobile Computers, ledande leverantör av stryktåliga datorer för krävande miljöer, annonserar idag att man har tecknat ett avtal om förvärv av sin franska säljpartner ID Work med tillträde i januari 2022. Sedan starten 2013 har ID Work framgångsrikt drivit försäljningen av JLT:s produkter i Frankrike genom ett landstäckande nätverk bestående av systemintegratörer och återförsäljare. Den franska marknaden har sedan dess vuxit till att bli en av JLT:s största och viktigaste marknader i Europa. JLT kommer att ta över ID Works verksamhet och etablera ett säljkontor med egen personal. Förvärvet gör att JLT kommer närmare sina kunder och säljpartners. Grundaren av ID Work som idag driver företaget kommer att ha ett fortsatt engagemang i JLT under de kommande åren. För mer informati
Better Collective initiates share buyback program to cover future payments relating to completed acquisitions and incentive programs8.12.2021 18:00:00 CET | Press release
Regulatory Release no. 38/2021 December 8, 2021 Better Collective A/S (the “Company”) has today initiated a share buyback program for up to 10 mEUR, to be executed during the period from December 9, 2021 to February 24, 2022. The purpose of the buyback program is to cover future payments relating to completed acquisitions and to cover established Incentive Plans. The buyback program is being initiated pursuant to the authorization granted by the shareholders at the annual general meeting held on April 26, 2021 to repurchase up to nominal 4,694,532 shares of EUR 0,01 each of the Company’s share capital in the period until the annual general meeting in 2022. The Company has appointed Nordea as lead manager of the buyback program. Under the agreement with Nordea, Nordea will purchase shares on behalf of the Company and will make its trading decisions independently of, and without influence by the Company. The buyback program is subject to the following terms: The purpose of the program is
Nextensa Nv/sa: Shares Repurchase8.12.2021 17:40:00 CET | Press release
NEXTENSA NV/SA: SHARES REPURCHASE Nextensa NV announces that the board of directors has decided to initiate a share repurchase programme to acquire up to 65,000 shares for a total amount of no more than 4,800,000 euros within the limits set down in the (renewed) share repurchase authorization as granted by the extraordinary general meeting of shareholders of 19 July 2021. The goal of the share repurchase is to enable Nextensa to meet its obligations resulting from the purchase plans for the benefit of its executive management. Nextensa recognizes the need for active and committed managers that are able to guide the transformation into a mixed property investor and developer. Furthermore, based on previous experience and current market practices and trends, the nomination and remuneration committee and the board of directors are convinced that managers are more engaged and committed when they are able to participate in the capital of Extensa NV, as this aligns their interests with those
Millicom files standard form for notification of major holdings8.12.2021 17:13:53 CET | Press release
Millicom files standard form for notification of major holdings Luxembourg,December 8, 2021 – Millicom International Cellular S.A. announced today the CSSF regulatory filing of the form: ANNEX A: Standard form for notification of major holdings (attachment) -END- For further information, please contact Press: Vivian Kobeh, Director Corporate Communications +1-786-628-5300 firstname.lastname@example.org Yocasta Valdez, Group Manager Digital Media & Communications +1-305-929-5417 email@example.com Investors: Michel Morin, VP Investor Relations +1-786-628-5270 firstname.lastname@example.org Sarah Inmon, Director Investor Relations +1-786-628-5303 email@example.com About Millicom Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of fixed and mobile services dedicated to emerging markets in Latin America and Africa. Millicom sets the pace when it comes to providing high-speed broadband and innovation around The Digital Lifestyle® services through its principal brand, TIGO. As
Volta Finance Limited - Result of AGM8.12.2021 16:04:30 CET | Press release
8 December 2021 Volta Finance Limited (VTA / VTAS) RESULTS OF THE FIFTEENTH ANNUAL GENERAL MEETING Volta Finance Limited announces that at the Fifteenth Annual General Meeting held earlier today all resolutions proposed were duly passed. One of these resolutions was a special resolution. The full text of the resolutions can be found in the Notice of Meeting contained within the Annual Report and Accounts 2021, copies of which are available for viewing on the Company’s website http://www.voltafinance.com. Further information on the votes cast for each resolution will be available on the Company’s website shortly. CONTACTS For the Investment Manager AXA Investment Managers Paris Serge Demay firstname.lastname@example.org +33 (0) 1 44 45 84 47 Company Secretary and Administrator BNP Paribas Securities Services S.C.A, Guernsey Branch email@example.com +44 (0) 1481 750 853 Corporate Broker Cenkos Securities plc Andrew Worne Daniel Balabanoff +44 (0) 20 7397 8900 ***** ABOUT V
New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer8.12.2021 15:30:00 CET | Press release
Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall survival (OS) in HR+/HER2- metastatic breast cancer (over 5 years) and proven OS benefit across patient subgroups1-5 Kisqali pooled data at the San Antonio Breast Cancer Symposium confirms OS benefit across most common genomic intrinsic subtypes of HR+/HER2- metastatic breast cancer, including the aggressive, ET-resistant HER2-enriched subtype6 Data supports rationale for HARMONIA, the first prospective, head-to-head Phase III trial seeking to identify the best therapeutic option between Kisqali and Ibrance®* for patients with the HER2-enriched subtype Kisqali remains the only CDK4/6i with consistent OS benefit across the entire MONALEESA program, regardless of site and number of metastases, prior treatment, endocrine partner, line of therapy or menopausal status1-5,7-8 Basel, December 8, 2021 — Novartis today announced new K